Phosphatidylserine and curcumin act synergistically to down-regulate release of interleukin-1β from lipopolysaccharide-stimulated cortical primary microglial cells

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 5, 2014, Pages 792-800

  Mercanti, Giulia ^a   Ragazzi, Eugenio ^a   Toffano, Gino ^b   Giusti, Pietro ^a   Zusso, Morena ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Curcumin; Cytokines; Isobolograms; Lipopolysaccharide; Microglia; Neuroinflammation; Phosphophatidylserine; Synergism

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; CURCUMIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOSOME; PHOSPHATIDYLSERINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL STIMULATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IC 50; IMMUNOCYTOCHEMISTRY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; RAT; RECEPTOR DOWN REGULATION; ANIMAL; BRAIN CORTEX; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; IC50; METABOLISM; NEWBORN; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; CELL SURVIVAL; CEREBRAL CORTEX; CURCUMIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICROGLIA; PHOSPHATIDYLSERINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84905575161     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140414121723     Document Type: Article

References (70)

1. Craft JM, Watterson DM, Van Eldik LJ. Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets 2005; 9(5): 887-900.
2. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998; 8(1): 65-72.
3. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005; 18(3): 315-21.
4. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv Exp Med Biol 1999; 468: 123-33.
5. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 2001; 24(8): 450-5.
6. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308 (5726): 1314-8.
7. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19(8): 312-8.
8. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3(1): 23-35.
9. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific proinflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol 2009; 210(1-2): 3-12.
10. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia 1993; 7(1): 111-8.
11. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003; 304(1): 1-7.
12. Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009; 158(3): 1021-9.
13. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002; 40(2): 133-9.
14. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem 2009; 108(6): 1343-59.
15. Jang, S, Johnson RW. Can consuming flavonoids restore old microglia to their youthful state? Nutr Rev 2010; 68(12): 719-28.
16. Choi DK, Koppula S, Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 2011; 16(2): 1021-43.
17. Pepeu G, Pepeu IM, Amaducci L. A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res 1996; 33(2): 73-80.
18. Gianotti C, Porta A, De Graan PN, Oestreicher AB, Nunzi MG. B-50/GAP-43 phosphorilation in hippocampal slices from aged rats: effects of phosphatidylserine administration. Neurobiol Aging 1993; 14(5): 401-6.
19. Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science 1984; 225(4668): 1365-70.
20. Pedata F, Giovannelli L, Spignoli G, Giovannini MG, Pepeu G. Phosphatidylserine increases acethilcholine release from cortical slices in aged rats. Neurobiol Aging 1985; 6(4): 337-9.
21. Toffano G, Leon A, Mazzari S, et al. Modification of noradrenergic hypothalamic system in rat injected with phosphatidylserine liposomes. Life Sci 1978; 23(10): 1093-101.
22. Vannucchi MG, Pepeu G. Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats. Neurobiol Aging 1987; 8(5): 403-7.
23. De Simone R, Ajmone-Cat MA, Nicolini A, Minghetti L. Expression of phosphatidylserine receptor and down-regulation of pro-inflammatory molecule production by its natural ligand in rat microglial cultures. J Neuropathol Exp Neurol 2002; 61(3): 237-44.
24. Hoffmann PR, Kench JA, Vondracek A, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 2005; 174(3): 1393-404.
25. Nolan Y, Martin D, Campbell VA, Lynch MA. Evidence of a protective effect of phosphatidylserine-containing liposomes on lipopolysaccharide-induced impairment of long-term potentiation in the rat hippocampus. J Neuroimmunol 2004; 151(1-2): 12-23.
26. Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 1992; 28(1): 61-6.
27. Engel RR, Satzger W, Günther W, et al. Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992; 2(2): 149-55.
28. Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging 1993; 5(2): 123-33.
29. Baumeister J, Barthel T, Geiss KR, Weiss M. Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress. Nutr Neurosci 2008; 11(3): 103-10.
30. Anand P, Kunnumakkara AJ, Newman R, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4(6): 807-18.
31. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65(11): 1631-52.
32. Jung KK, Lee HS, Cho JY, et al. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci 2006; 79(21): 2022-31.
33. Jin CY, Lee JD, Park C, Choi YH, Kim GY. Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharidestimulated BV2 microglia. Acta Pharmacol Sin 2007; 28(10): 1645-51.
34. Zhang LJ, Wu CF, Meng XL, et al. Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci Lett 2008; 447(1): 48-53.
35. Tocharus J, Jamsuwan S, Tocharus C, Chanqtam C, Suksamran A. Curcuminoid analogs inhibit nitric oxide production from LPSactivated microglial cells. J Nat Med 2012; 66(2): 400-5.
36. Witkin JM, Li X. Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy. CNS Neurol Disord Drug Targets 2013; 12(4): 487-97.
37. Witkin JM, Leucke S, Thompson LK, et al. Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin. CNS Neurol Disord Drug Targets 2013; 12(4): 498-505.
38. Skaper SD, Argentini C, Barbierato M. Culture of neonatal rodent microglia, astrocytes, and oligodendrocytes from cortex and spinal cord. Methods Mol Biol 2012; 846: 67-77.
39. Lee SJ, Lee S. Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy 2002; 1(2): 181-91.
40. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003; 17(1): 13-9.
41. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173(6): 3916-24.
42. Palatini P, Viola G, Bigon E, Menegus AM, Bruni A. Pharmacokinetic characterization of phosphatidylserine liposomes in the rat. Br J Pharmacol 1991; 102(2): 345-50.
43. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63.
44. Facci L, Skaper SD. Culture of rat cerebellar granule neurons and application to identify neuroprotective agents. Methods Mol Biol 2012; 846: 23-37.
45. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953; 3(6): 285-90.
46. Minto CF, Schnider TW, Short TG, et al. Response surface model for anesthetic drug interactions. Anesthesiology 2000; 92(6): 1603-16.
47. Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 2006; 319(1): 1-7.
48. Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 1995; 105(2-3): 161-79.
49. Greco WR, Faessel H, Levasseur L. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? J Natl Cancer Inst 1996; 88(11): 699-700.
50. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 2004; 1(1): 14.
51. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 2009; 29(13): 3974-80.
52. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron 2009; 64(1): 110-22.
53. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140(6): 918-34.
54. Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81(6): 1285-97.
55. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55(5): 453-62.
56. Cunningham C. Microglia and neurodegeneration: The role of systemic inflammation. Glia 2013; 61(1): 71-90.
57. Fiebich BL, Lieb K, Engels S, Heinrich M. Inhibition of LPSinduced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol 2002; 132(1-2): 18-24.
58. Lee YB, Schrader JW, Kim SU. p38 map kinase regulates TNFalpha production in human astrocytes and microglia by multiple mechanisms. Cytokine 2000; 12(7): 874-80.
59. Han IO, Kim KW, Ryu JH, Kim WK. p38 mitogen-activated protein kinase mediates lipopolysaccharide, not interferon-gamma-induced inducible nitric oxide synthase expression in mouse BV2 microglial cells. Neurosci Lett 2002; 325(1): 9-12.
60. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20(6): 252-8.
61. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15): 1066-71.
62. Zingarelli B. Nuclear factor-kappaB. Crit Care Med 2005; 33(12 Suppl): S414-6.
63. Ajmone-Cat MA, De Simone R, Nicolini A, Minghetti L. Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic AMP responding element binding protein and nuclear factorkappaB activation in resting and activated microglial cells. J Neurochem 2003; 84(2): 413-6.
64. De Simone R, Ajmone-Cat MA, Minghetti L. Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction. Mol Neurobiol 2004; 29(2): 197-212.
65. Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogenactivated protein kinases in microglia. Glia 2002; 40(2): 175-83.
66. Ma HM, Wu Z, Nakanishi H. Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. Lab Invest 2011; 91(6): 921-31.
67. Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 2007; 82(4): 968-74.
68. Grabovsky Y, Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 2004; 310(3): 981-6.
69. Yang F, Lim GP, Begum AN, etal. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280(7): 5892-901.
70. Begum AN, Jones MR, Lim GP, et al. Curcumin structurefunction, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008; 326(1): 196-208.